JPMORGAN CHASE & CO - Feb 28, 2025 SCHEDULE 13G/A Report for Revance Therapeutics, Inc. Common Stock, par value $0.001 per share (RVNC)

Filing Manager: JPMORGAN CHASE & CO
Reporting Manager: JPMORGAN CHASE & CO.
Security: Revance Therapeutics, Inc. Common Stock, par value $0.001 per share
Symbol: RVNC
Disclosed Ownership: 0 shares
Ownership: 0%
Form type: SCHEDULE 13G/A
Date filed: 3/6/2025, 10:52 AM
Date of event: Feb 28, 2025
Previous filing: Feb 11, 2025
SEC: View on sec.gov

Reporting Managers (1)

Name	Ownership	Shares Owned	sole voting power	shared voting power	Signature	Title	CIK
JPMORGAN CHASE & CO.	0%	0	0	0	Rachel Tsvaygoft	Vice President

Showing 1 to 1 of 1 entries